

Effective December 1, 2025, the Alberta Biosimilars Initiative will be updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

Addition of omalizumab biosimilar – all adult patients on Xolair must switch by June 1, 2026

1. Update to Alberta Drug Benefit List (ADBL)

On December 1, 2025, a new omalizumab biosimilar drug, Omlyclo, was listed on the Alberta Drug Benefit List (ADBL) for the treatment of Asthma and Chronic Idiopathic Urticaria and will be subject to the Alberta Biosimilar Initiative.

2. Coverage

Effective December 1, 2025, all new omalizumab starts for Asthma or Chronic Idiopathic Urticaria are covered with a biosimilar version of omalizumab. Adult patients currently taking Xolair will be required to switch to a biosimilar version by June 1, 2026 to maintain coverage for this molecule through their Alberta government-sponsored drug plan.